Status:

ACTIVE_NOT_RECRUITING

Optimising Protection for Pregnant Women and Infants With Maternal Vaccination

Lead Sponsor:

Women's and Children's Hospital, Australia

Collaborating Sponsors:

Sanofi Pasteur, a Sanofi Company

Conditions:

Obesity

Eligibility:

FEMALE

18+ years

Brief Summary

This study has been designed to investigate if: 1. BMI affects the immunogenicity of influenza and pertussis vaccines given during pregnancy. 2. If pertussis vaccine co-administered with influenza va...

Detailed Description

A clinical observation study to determine whether obesity during pregnancy is associated with altered immunogenicity of influenza and pertussis vaccines during pregnancy. The study will also assess va...

Eligibility Criteria

Inclusion

  • Participants who, in the opinion of the study staff, can and will comply with the requirements of the protocol (eg. return for follow-up visits, blood collection etc).
  • Pregnant women aged 18 years and over at the time of vaccination.
  • Able to understand the information sheet and provide a written informed consent.

Exclusion

  • Any major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in the study, or interfere with the evaluation of the study objectives.
  • History of serious medical conditions (eg cardiac, respiratory, renal, hepatic disorders, diabetes requiring treatment with insulin).
  • History of seasonal influenza or dTpa vaccination within the last 6 months prior to enrolment.
  • History of any immunosuppressive condition or currently on immunosuppressive medication.
  • Any contraindication to influenza or dTpa immunisation.
  • Anaphylaxis following a previous dose of any influenza or pertussis containing vaccine.
  • History of anaphylaxis to egg.
  • Past history of Guillain Barre Syndrome.
  • Bleeding diathesis or condition associated with prolonged bleeding that may contraindicate intramuscular injection or blood draw.
  • Receipt of immunoglobulins, blood or blood products within the past 6 months.

Key Trial Info

Start Date :

August 28 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 1 2024

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT03457194

Start Date

August 28 2018

End Date

March 1 2024

Last Update

January 31 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Women's and Children's Hospital

North Adelaide, South Australia, Australia, 5006

Optimising Protection for Pregnant Women and Infants With Maternal Vaccination | DecenTrialz